title: Tocilizumab postpones the start of hemodialysis compared to conventional oral treatment in amyloid A amyloidosis patients with advanced renal insufficiency by suppressing serum SAA levels.
authors.affiliation: a Department of Rheumatology , Higashiosaka City General Hospital , Higashiosaka city , Osaka , Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Uda
authors.affiliation: b Department of Rheumatology , Higashiosaka City General Hospital , Higashiosaka city , Osaka , Japan.|c Department of Rheumatology , Shiraishi Hospital , Imabari City , Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Saiki
mesh_terms: D000368:Aged; D000686:Amyloidosis / Q000097:blood* / Q000188:drug therapy* / Q000628:therapy; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000097:blood* / Q000188:drug therapy* / Q000628:therapy; D000685:Serum Amyloid A Protein / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000685:Serum Amyloid A Protein; C502936:tocilizumab